The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

This study (called the Liding Study) is testing whether adding an immunotherapy drug (tislelizumab) and a targeted drug (pegylated liposomal doxorubicin, or PLD) to standard chemotherapy (XELOX) before surgery improves outcomes for patients with resectable (operable) stage III stomach cancer. The aim is to shrink the tumor before surgery to improve the chance of a complete cure. **You may be eligible if:** - You are 18–75 years old - You have been diagnosed with stage III stomach (gastric) adenocarcinoma confirmed by biopsy - Your cancer is HER2-negative and PD-L1-positive (specific lab markers on the tumor) - Your overall health and organ function are adequate for major surgery - Your heart function is normal (ejection fraction ≥50%) **You may NOT be eligible if:** - Your cancer has spread to distant organs or lymph nodes beyond what is classified as stage III - Your cancer is HER2-positive - You have serious heart, liver, kidney, or blood count issues - You have autoimmune disease or are on immunosuppressive drugs Talk to your doctor to see if this trial is right for you.